(Q40154356)

18 September 2017

title

Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis (English)

1 reference

18 September 2017

0 references

Yohei Ichimura

1

1 reference

18 September 2017

Yoshihide Asano

2

1 reference

18 September 2017

Kaname Akamata

3

1 reference

18 September 2017

Takehiro Takahashi

4

1 reference

18 September 2017

Shinji Noda

5

1 reference

18 September 2017

Takashi Taniguchi

6

1 reference

18 September 2017

Tetsuo Toyama

7

1 reference

18 September 2017

Naohiko Aozasa

8

1 reference

18 September 2017

Hayakazu Sumida

9

1 reference

18 September 2017

Yoshihiro Kuwano

10

1 reference

18 September 2017

Koichi Yanaba

11

1 reference

18 September 2017

Yayoi Tada

12

1 reference

18 September 2017

Makoto Sugaya

13

1 reference

18 September 2017

Shinichi Sato

14

1 reference

18 September 2017

Takafumi Kadono

15

1 reference

18 September 2017

publication date

29 November 2013

1 reference

Archives of Dermatological Research

18 September 2017

published in

1 reference

18 September 2017

volume

306

1 reference

18 September 2017

issue

4

1 reference

18 September 2017

page(s)

331-338

1 reference

https://scigraph.springernature.com/pub.10.1007/s00403-013-1431-9

18 September 2017

exact match

0 references

cites work

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Future treatments in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Release of CXC-chemokines by human lung microvascular endothelial cells (LMVEC) compared with macrovascular umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Chemokine-cytokine cross-talk. The ELR+ CXC chemokine LIX (CXCL5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase-NF-kappa B pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Elevated matrix metalloproteinase-9 in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Topical antisense oligonucleotide therapy against LIX, an enterocyte-expressed CXC chemokine, reduces murine colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by decreasing joint vascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Serum levels of ADAM12-S: possible association with the initiation and progression of dermal fibrosis and interstitial lung disease in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-013-1431-9

10.1007/S00403-013-1431-9

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference